Inflammation Research and Drug Development | Charles River

World Congress on Inflammation 

Inappropriately triggered or incompletely controlled inflammatory responses are a major cause of disease, impaired quality of life and morbidity. Charles River Discovery Services has the experience and expertise to help advance your understanding of the cellular processes involved and identify therapeutic targets and markers of disease to develop new approaches for diagnosis, prevention and treatment.

Additionally, the role of inflammation in such widespread chronic diseases such as atherosclerosis, metabolism and diabetes is an area of intense investigation. Our scientists offer in-depth expertise involving the interplay of these diseases and the impact of inflammation in these therapeutic areas. With an expansive catalog of high-quality in vitro, biomarker, PK and toxicology services, we provide seamless drug development for your discovery program.

Available inflammation models for evaluation of your test articles include the following:

Acute Inflammation

  • Carrageenan Footpad Edema (CFE)
  • Delayed-Type Hypersensitivity (DTH)
  • LPS-Induced Cytokine Release
  • Sponge Granuloma
  • Thioglycollate-Induced Peritonitis (TIP)
  • Bleomycin-Induced Pulmonary Fibrosis
  • Experimental Autoimmune Encephalomyelitis (EAE)
  • Trinitrophenyl-ovalbumin immunization (TNP-OVA)
  •  Acute Lung Injury


Rheumatoid Arthritis

  • Rat collagen-induced arthritis (rCIA)
  • Mouse collagen-induced arthritis (mCIA; with or without LPS synchronization)
  • Mouse collagen antibody-induced arthritis (CAIA)
  • Adjuvant/pristine-induced arthritis (AIA)


With extensive drug development experience driving our model validation, Charles River is able to offer study models that ensure disease progression as well as positive control and standards of care responses. In addition, our wide range of supporting analysis can expand your study outcomes for faster, more effective analysis of your drug candidates.

For more information on how we can support your inflammation research, please contact us at 1.877.CRIVER.1 or askcharlesriver@crl.com.


Related Information

Discovery Services Overview

Inflammation and Immunology Datasheet

Rheumatoid Arthritis Datasheet

Cardiovascular Diseases Technical Sheet

Oncology Datasheet

Central Nervous System Datasheet

Models of Behavior Datasheet

Webinar Replay - Markers of Inflammation - (June 2011)

Webinar Replay - Preclinical Pulmonary Inflammation Models (October 2010)

Webinar Replay - Inflammation Models in Preclinical Drug Research: Traditional Endpoints to Translational Imaging (September 2010)

Discover the full range of Charles River Products and Services
The Source

For more information, contact us at:

1.877.CRIVER.1 (1.877.274.8371)
askcharlesriver@crl.com

view all

News & Events

view all
May 13 - High-Throughput Screening for CNS ...
May 08 - Comparability Studies for Monoclon...
May 28-Jun 01 - Kobe, Japan - Joint Meeting of the International Bone and Mineral Socie...
May 23-May 23 - East Lansing, Michigan, USA - The Ins and Outs of Transgenic Colongy Ma...

Charles River Laboratories, Inc.